Xcout Intel
MABION SA MABION competitors & alternatives
The 12 closest competitors and alternatives to MABION SA MABION among biotech companies — ranked by similarity to what MABION SA MABION actually does, not by market-cap band.
Subscribe to see MABION SA MABION’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About MABION SA MABION
Mabion SA operates as a biotechnology company and Contract Development and Manufacturing Organization (CDMO) that provides services encompassing process development, analytics, and drug substance manufacturing. The company specializes in working with biologics such as biosimilars, antibodies, antibody-drug conjugates (ADCs), and recombinant therapeutic proteins to serve biopharmaceutical clients.
MABION SA MABION at a glance
MABION SA MABION is a biotech company headquartered in United Kingdom. Xcout tracks 13 named people at MABION SA MABION, including Dr. Thomas Richter (CEO of BTI).
MABION SA MABION leadership
- Dr. Thomas RichterCEO of BTI
- Gregor KawaletzChief Executive Officer
- Detlef BehrensChief Business Affairs Officer
- Joaquín Santos BenitoChief Transformation Officer
- Jonas Skjødt MøllerEx-Head of Advance Technologies at Sartorius
- Dr. Firelli AlonsoEx-Executive Director at Pfizer
7 more named people on record for MABION SA MABION, with roles, board committees and tenure — see the full roster →
Top 12 MABION SA MABION competitors
Ranked by semantic similarity — how close each company is to MABION SA MABION by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Polpharma Biologics is a biotechnology company that develops and manufactures biosimilar medicines to improve patient access to biopharmaceuticals. Operating from Switzerland, the company manages a broad portfolio of biosimilars targeting major therapeutic areas and collaborates with global biopharmaceutical partners to bring these treatments from concept to commercial supply.
Similar biotech company
Samsung Biologics operates as a global contract development and manufacturing organization (CDMO) providing end-to-end biopharmaceutical services to pharmaceutical and biotech companies. The company offers a range of services including cell line development, process development, analytical testing, drug substance and drug product manufacturing, and advanced modalities like bioconjugation and mRNA.
Similar biotech company
AGC Biologics is a global contract development and manufacturing organization (CDMO) that provides services for protein-based biologics and advanced therapies, including mammalian and microbial production, viral vectors, cell therapy, plasmid DNA, and mRNA. The company supports biopharmaceutical developers by offering process development, analytical formulation, cGMP manufacturing, and fill-finish services to help bring life-changing treatments to market.
Similar biotech company
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
Similar biotech company
Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.
Similar biotech company
Rentschler Biopharma SE is a contract development and manufacturing organization (CDMO). It is part of Dr. Rentschler Holding GmbH & Co. KG and its employees make up the majority of the 1300 workers employed by the parent organization.
Similar biotech company
Evotec is a life science company that provides drug discovery and preclinical development services, working across modalities from small molecules to biotherapeutics. Through its subsidiary Just - Evotec Biologics, the company focuses on the design, development, and manufacturing of biologics to make therapies more accessible and affordable for partners in the pharmaceutical and biotechnology industries.
Similar biotech company
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provides oncology products, including 9MW2821, a Nectin-4 targeting drug candidate in the Phase III clinical trials for the treatment of cervical cancer; 7MW3711, a B7-H3 targeting ADC for the treatment of advanced malignant solid tumors; and 7MW4911, an ADC that targets CDH17. In addition, the company offers immunology products comprising 9MW1911, an anti-ST2 antibody that is in Phase I clinical trial for the treatment of COPD, and 9MW3811, an anti-IL-11 antibody that is in Phase I clinical trial. Its bone disorder product pipeline consists of 1MW5011, an oral tablet for the treatment of osteoarthritis. Additionally, it provides ophthalmology products include 9MW0813, a recombinant VEGF receptor-antibody fusion protein for the treatment of ocular diseases related to vascularization; 9MW0211, a recombinant anti-VEGF humanized monoclonal antibody injection that is in Phase III clinical trials for the treatment of neovascularization-related eye diseases, such as neovascular age-related macular degeneration. Further, the company's hematology product comprises 9MW3011, a recombinant humanized anti-TMPRSS6 monoclonal antibody that is in Phase I clinical trials for the treatment of polycythemia vera and iron overload disorders, including beta-thalassemia. The company was founded in 2017 and is headquartered in Shanghai, China.
Biotechnology
Bloom Labs Bio Inc. specializes in the development and manufacturing of biologics, biosimilars, recombinant proteins, monoclonal antibodies, prebiotics, and probiotics. Utilizing modern biotechnology platforms and advanced infrastructure, the company serves the pharmaceutical and life sciences sectors with therapeutic and health and wellness solutions.
Similar biotech company
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
Similar biotech company
Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Similar biotech company
Alvotech specializes in the development and manufacturing of biosimilars to expand access to affordable biologic medicines for patients worldwide. The company utilizes a vertically integrated approach spanning from cell line development to fill and finish manufacturing.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of MABION SA MABION and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for MABION SA MABIONand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →